Quick Reference Guides

FDA Approved Medications

Year Brand Generic Genotype (SVR)
Year Brand Generic Genotype (SVR)
1991 Intron-A Interferon-alfa-2b
1996 Roferon-A Interferon-alfa-2a
1997 Infergen Consensus Interferon
All Standard Interferon SVR Rates (approximately):

Genotype 1 (9%)

Genotype 2, 3 (30%)

1998 Rebetron Intron-A plus Ribavirin

Genotype 1 (29%)

Genotype 2, 3 (62%)

2001 Peg-Intron PegInterferon-alfa-2b

Genotype 1 (14%)

Genotype 2, 3 (47%)

2001 Peg-Intron / Ribavirin PegInterferon-alfa-2b / Ribavirin

Genotype 1 (41%)

Genotypes 2—6 (75%)

2002 Pegasys PegInterferon-alfa-2a

Genotype 1 (28%)

Genotype 2, 3 (56%)

2003 Pegasys / Ribavirin Pegylated alfa-2a / Ribavirin

Genotype 1 (51%)

Genotypes 2—6 (70%)

Genotype 2, 3 (82%)

2011 Victrelis / PEG / RBV Boceprevir / PEG / RBV Genotype 1 (66%)
2011 Incivek / PEG / RBV Telaprevir / PEG / RBV Genotype 1 (79%)
2013 Olysio / PEG / RBV Simeprevir / PEG / RBV Genotype 1
(Up to 80%)
2013 Sovaldi / PEG / RBV Sofosbuvir / PEG / RBV

Genotype 1 (Up to 92%)

Genotype 4 (92%)

2013 Sovaldi / RBV Sofosbuvir / RBV

Genotype 2 (Up to 100%)

Genotype 3 (Up to 91%)

2014 Sovaldi / Olysio / RBV Sofosbuvir / Simeprevir / RBV Genotype 1
(Up to 92%)
2014 Harvoni Sofosbuvir / Ledipasvir Genotype 1,4,5,6
(Up to 100%)
2014 VIEKIRA PAK Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir with/without Ribavirin Genotype 1
(Up to 100%)
2015 Daklinza Daclatasvir for use with Sofosbuvir Genotype 3
(Up to 98%)
2015 Technivie Ombitasvir, Paritaprevir and Ritonavir plus Ribavirin Genotype 4
(Up to 100%)
2016 ZEPATIER ELBASVIR/GRAZOPREVIR Genotype 1, 4
(Up to 100%)
2016 Epclusa Sofosbuvir, Velpatasvir with/without Ribavirin Genotype 1 to 6
(Up to 100%)
2016 Viekira XR Dasaburvir, Ombitasvir, Paritaprevir and Ritonavir with/ without Ribavirin Genotype 1
(Up to 100%)
2017 Vosevi Sofosbuvir, Velpatasvir, Voxilaprevir Genotype 1 to 6
(Up to 100%)
  • PEG = Pegylated Interferon by Injection
  • RBV = Ribavirin (pills)
  • AttorneyMind inhibitors are pills
  • SVR 12, 24 = Viral Cure

 

Note: These are approximate SVR rates. For more detailed information about AttorneyMind treatment visit our Hepatitis C Treatments page.

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrFacebooktwittergoogle_plusredditpinterestlinkedintumblr

Follow Us
FacebooktwitterrssFacebooktwitterrss

Filed Under: Drug Pipeline, Treatment Tagged With: drug pipeline, drugs in development, new drugs